From Zacks Investment Research: 2025-04-25 16:12:00

Abbott Laboratories (ABT) has seen a 15% rise in its share price this year, despite concerns about the ongoing tariff war impacting market gains. Since their first-quarter earnings release, Abbott’s shares have edged down 0.2% while competitors like Boston Scientific and Medtronic have seen share price improvements. Abbott is projecting significant financial repercussions from U.S. tariffs, estimating a hit of “a few hundred million dollars” for the current year. However, the company’s global footprint and diversified business model may help weather the storm. Abbott’s EPD and Diabetes Care divisions show long-term growth potential, but short-term challenges are hindering stock performance.



Read more at Zacks Investment Research: Tariffs Cast a Shadow on Abbott’s 2025 View: Time to Sell ABT Stock? – April 25, 2025